PureTech Health

PRTC: 280.00 +1.00 (+0.36%) delayed: 18 Sep 2019, 10:37

Trade now

PureTech Health Fundamentals

Share Price Information

Name PureTech Health
Epic PRTC
Sector Biotechnology
ISIN GB00BY2Z0H74
Activites PureTech Health plc is an advanced biopharmaceutical company developing BIG medicines for dysfunctions of the Brain-Immune-Gut axis. The Company has gained deep insights into the connection between these systems and the resulting role in diseases that have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies with an unbiased, non-binary, and capital efficient R&D model across its affiliates and its internal labs. PureTech's affiliates include seven clinical-stage platforms, including one product that has been cleared by the US Food and Drug Administration (FDA) and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programmes. The PureTech Health pipeline includes ground-breaking platforms and therapeutic candidates that were developed in collaboration with some of the world's leading experts. PureTech's internal research and development is centred on tissue-selective immunomodulation for the treatment of oncology, autoimmune, and CNS-related disorders, with a near-term focus on targeting newly-discovered, foundational immunosuppressive mechanisms in oncology and novel approaches that harness the lymphatic infrastructure.
Index FTSE 250

Key numbers

Latest Share price (p) 280.00 Net gearing (%) 35.71
Market capitalisation (£m) 788.49 Gross gearing (%) 62.20
Shares in issue (m) 282.61 Debt ratio 5.13
P/E ratio -17.44 Debt-to-equity ratio 0.03
Total dividends per share (p) 0.00 Assets / equity ratio 2.65
Dividend yield (%) 0.00 Price to book value 4.72
Dividend cover 0.00 ROCE (%) -38.89
Earning per share (p) -16.00 EPS growth (%) -23.08
52-week high / low (p) 307.00 / 155.00 DPS growth (%) n/a

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
31 Dec 2018 Full Year 21 -71 -16.00 USD
31 Dec 2017 Full Year 3 -71 -13.00 USD
31 Dec 2016 Full Year 4 -82 -21.00 USD

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year

Contact details

Company name PureTech Health
Address 5th Floor, 6 St Andrew Street, London EC4A 3AE.
Telephone +1 617 456 0032
Website http://www.puretechhealth.com/

Advisors

Company's broker Jefferies Hoare Govett
Company's joint broker Peel Hunt
NOMAD n/a
Registrar Computershare Investor Service
Auditors KPMG Audit
Solicitors DLA Piper UK LLP

Directors

Appointed Director Position
08 May 2015 Daphne Zohar Chief Executive Officer
08 May 2015 Stephen Muniz Finance Director
19 Jun 2015 Joichi Ito Non-Executive Chairman
19 Jun 2015 Christopher Viehbacher Non-Executive Director
19 Jun 2015 Dr Bennett Michael Shapiro Non-Executive Director
19 Jun 2015 Marjorie Morris Scardino Non-Executive Director
19 Jun 2015 Dr Robert Langer Non-Executive Director
19 Jun 2015 Dr John LaMattina Non-Executive Director
19 Jun 2015 Dr Raju Kucherlapati Non-Executive Director

Company financials

Assets (£m) 2018 2017 2016
Reporting date 31 Dec 2018 31 Dec 2017 31 Dec 2016
Tangible assets 8 7 7
Intangible asssets and goodwill 3 3 4
Investments and other non-current assets 171 132 0
Total non-current assets 182 142 11
Inventory / work in progress 0 0 0
Trade and other receivables 1 2 0
Cash and equivalents 117 73 63
Other current assets and asset held for resale 141 124 225
Total of all assets 442 340 299
Liabilities (£m) 2018 2017 2016
Short term liabilities 266 274 204
Long term liabilities 9 2 2
Other liabilites / pension etc 0 0 0
Total of all liabilities 275 276 206
Net assets (£m) 2018 2017 2016
Net assets 167 64 92
Equity (£m) 2018 2017 2016
Share capital 5 5 5
Minority interests -109 -150 -85
Retained earnings -168 -128 169
Share premium account 278 182 182
Other equity 159 156 -178
Total equity 167 64 92
Cash Flow (£m) 2018 2017 2016
Cash from operating activities -73 -89 -58
Cashflow before financing -112 -5 -101
Increase / decrease in Cash 44 10 -72
Income (£m) 2018 2017 2016
Turnover 21 3 4
Cost of sales 0 0 0
Gross profit 0 0 0
Operating profit -104 -115 -74
Pre-tax profit -68 -71 -83
Profit / loss for the year -71 -71 -82